Labetuzumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | carcinoembryonic antigen |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) |
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
References[]
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
- ^ http://www.cancer.gov/drugdictionary?cdrid=692828
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs